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Heparin monitoring
Abstract. Three automated spectrophotometric heparin assays were inyestigated. The day-
to-day reproducibilities in routine laboratory use were compared with two commercial man-
ual kits for heparin determination. Regression analysis of the activated partial thromboplastin
time (APTT) on results of any of the heparin assays shows that the heparin concentration
cannot be deduced from the APTT values found in patients receiving heparin. The automated
heparin assays that employ thrombin and Chromozym-Th or 5-2238 were found to be most
suitable for routine heparin determination. Heparin concentrations obtained from assays
based on factor Xa inactivation were not signihcantly different from those employing throm-
bin (p < 0.01), but revealed a wider standard deviation. The relationship between APTT and
heparin level found was not related to the plasma antithrombin III concentration. The extra
antithrombin III that is added in the assays had to be freed of heparin neutralising activity to
obtain reliable estimates of the heparin concentration in the low range (0-200 U/l).
Haemostasis 14: 195-204 (1984)
Introduction
Although the first amidolytic heparin as-
say was described in 1976 [], methods based
on this principle are not yet in general use. In
daily practice, the activated partial thrombo-
plastin time (APTT) is usually employed to
determine the dosage of heparin. The APTT
I We would like to acknowledge the assistance of-
fered by W.T.M. van Bergen Henegouwen.
@ 1984 S. KargerAG, Base.
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is known to be influenced by many factors
besides heparin. We found a remarkable in-
terindividual variation of the APTT in re-
sponse to standard heparin levels. Spectro-
photometric heparin assays are less subject to
such interindividual variations [2]. There-
fore, we further investigated the reliability of
such heparin determinations.
In an earlier paper we described 3 auto-
mated spectrophotometric heparin assays
(using substrates Chromozym-Th and S-
2238 with thrombin, and 5-2222 with fac-
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tor Xa) [3]. Before releasing these new assays
for routine use, day-to-day reproducibility
was determined in comparison with 2 avail-
able manual heparin kits. Reproducibility
was tested with 3 heparinised plasma pools
and with 2 commercially available control
plasmas.
The purified antithrombin III (AIIII), a
reagent used in the spectrophotometric hepa-
rin assays in this study, showed a disturbing
heparin neutralising effect. This unexpected
phenomenon was investigated and compen-
sated for in subsequent assays.
To study the agreement between heparin
assays based on thrombin and Xa inactiva-
tion performed on patient plasmas, the hepa-
rin levels were determined in plasmas in
which APTT was determined routinely.
Since the APTT is used to control heparin
therapy, the relationships between the APTT
and the heparin assays were also determined.
To investigate whether variations in plasma
ATIII level are associated with the relation-
ships found, we measured the ATIII activity
in every plasma.
To determine remaining thrombin activ-
ity in either the heparin assay or the ATIII
assay, several chromogenic substrates can be
used. Two chromogenic substrates (Chromo-
zym-Th and 5-2238) are compared here.
Materials and Methods
Citrated Plasma. By means of a vacuum system
with a multi-sample needle, blood was drawn from the
antecubital vein. The first tube was not used in this
study. Next a second tube (Venoject, black stopper,
4.5m1, 3.8o/o tri-Na-citrate) was drawn for routine
clotting determinations. Within l5 min the latter sam-
ple was centr i fuged (10min,3,500Sr, 15'C). The
plasma thus obtained contained fewer than 3 X lOe
platelets/I.
Pooled Plasma. Equal volumes of citrated plasma
from 30 healthy donors were mixed and stored at
-70 
"C in aliquots of 1 ml.
ATIII from KabiVitrum, Amsterdam, contained
lOU per vial. One unit was defined as the activity
found in I ml plasma. The contents of each vial were
dissolved in l0ml distilled water. Where indicated.
100 pl heparin (2,500 U/l) were added to tirate hepa-
rin neutralisation.
Thrombin. We used bovine thrombin from Roche,
Basel. The contents ofeach vial (120 USP units) were
dissolved in 2.4 ml of distilled water. Before use I vol
of thrombin was diluted with 5 vol of buffer I.
Factor Xa used was bovine factor Xa from Kabi
Vitrum. Amsterdam. The contents of each vial
(71 nkat) were dissolved in 10 ml of distilled water.
Heparin was obtained from Leo (Emmen, Hol'-
land). According to the manufacturer, the solution
contained 5,000 USP U/ml of the sodium salt. Dilu-
tions were made with buffered saline (147 m-l|1 NaCl,
6.52 mM Na2HPO4, 1 .62 mM KH2PO4, pH 7.35).
Control plasma for heparin assays: Precichrom I
and II (Boehringer-Mannheim, Amsterdam). The con-
tents of each vial were dissolved in 0.5 ml distilled
water.
Reproducibility. Heparin was added to a citrate
plasma pool, to make 3 pools containing approxi-
mately 50, 300 and 800 U/1. These pools were frozen
in aliquots of I ml at -70 "C. On 25 days I ml of each
pool was thawed at room temperature and assessed in
duplicate. Every day a reference curve was made of
nonheparinised pooled normal plasma spiked with
known amounts of heparin. With each assay the two
control plasmas were determined as well.
APTT Reagenl. Diagen Kaolin/platelet substitute
from Diagnostic Reagents Ltd., Thame, Oxon, En-
gland.
C hromogenic substrates used were: Tos-Gly-Pro-
Arg-pNA (Chromozym-Th, Boehringer-Mannheim,
Amsterdam), Benz-Ile-Glu-Gly-Arg-pNA' HCI and
H-D-Phe-Pip-Arg-pNA . 2HCl (3-2222 and 5-2238
both from KabiVitrum. Amsterdam). Each ofthe sub-
strates was dissolved in distilled water.
Bulfer I (pH 8.4 and I0.2) contained di-Na-EDTA
(7.5mM), Tris-HCl (50mn4 and NaCl (l75mM.
Buffer II was as buffer I but with heparin (3 U/1).
Manual chromogenic heparin assalrs were per-
formed with a photometer with a thermostatically
controlled cuvette rack (Beckman No. 25), connected
to a recorder (Beckman No. 2000).
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Table I. Analytical conditions of the heparin assays
Assay
Chrom-Th
manualt
s-2222
manual2
Chrom-Th
automated
s-2238 5-2222
automated automated
Predilution, U.l buller I
Predilution, pI plasma
AI-II I  (1.0 U/lml),  pl
Diluted plasma, pl
Buffer I, pl
Preincubation time, s
Temperature, 'C
Enzyme amount, pl
Xa, nkaVml
IIa, USP units/ml
Incubation time, s
Substrate, pl
Concentration, mmol/l
Measuring time, s
Wavelength, nm
10
2;
1,000
0.03
180
100
1 . 5
30
405
800
100
100
200
180
5 I
100
7.r
45
200
2.0
30
405
550
50
400
60
140
4563
25
100
8.33
J J "
100
0.95
22
405
550
50
400
75
t25
4563
25
100
8.33
333
100
0.75
22
405
800
100
100
r00
r00
4564
25
200
7 . r
334
100
1.0
22
405
I Boehringer Diagnostica: Produkt informatie TC Heparine, 1980.
2 Kabi Diagnostica: Determination of heparin in plasma wtth S-22z2,laboratory Instruction, Apnl 1977.
3 For the low range (0-200 U/l) the preincubation time is 390 s and the incubation time is 99 s.
a For the low range (0-200 U/l) the preincubation time is 324 s and the incubation time is 165 s.
Determinations with the heparin krrs TC-heparin
02337 14, Boehringer and CoatesVHeparin, KabiVi-
trum, were performed according to the instruction for
kinetic measurements, as supplied by the manufactur-
ers,
Automated Chromogenic Heparin,4ssays. These
were performed on a 'Corona' batch analyzer (Clini
con Amsterdam) as reported before [3]. For testing the
reproducibility, the method with reference measure-
ments in the normal range (0-800 U of heparin/l plas-
ma) were used. Heparin neutralising capacity in the
ATIII reagent was tested with a method adapted for
measuring low heparin (0-200) concentrations by an
increase of the incubation time. This causes the refer-
ence curve to steepen, thus increasing the sensitivity of
the assay. The higher heparin concenrations (250-
800) cannot be determined reliably, because the en-
zyme concentration becomes rate limiting on pro-
longed incubation. The conditions ofthe heparin as-
says are summarised in table I. Reference samples
Table II. Analytical conditions for the automated
ATIII assays
Chromogenic substrate
Chromozym-Th/S-2238
Predilution, d bufferl 900
Predilution, pI plasma 100
Diluted plasma, pl 15
Buffer II, pl 400
Preincubation time, s 126
Temperature, "C 25
Enzyme amount, pl 100
IIa. USP units/ml 8.33
Incubation time, s 330
Substrate, pl 100
Concentration (mmol/l), pl 0.95/0.75
Measuring time, s 22
Wavelength, nm 405
t " '  t ' t t ' .l 1i:';'i1 ' :
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Table IIIa. Dilution procedure for reference sam-
ples of heparin assays
were made of pooled normal plasma spiked with
known amounts of the heparin of the same batch as we
desired to determine, as indicated in table IIIa.
Automated spectrophotometric ATIII assays were
performed on the same analyzer. The reaction condi-
tions are given in table II. Reference samples were
made from diluted pooled nonnal plasma as indicated
in table IIIb. The calibration curve was a linear fit
through the reference measurements.
Clouing lssays. APTT assays were performed as
indicated by the manufacturer of the reagent, on a
'KCl0' coagulometer (Salm en Kipp, Breukelen, The
Netherlands). Plasma was incubated with the APTT
reagent in a plastic tube. After recalcification, the clot-
ting time was measured.
Statistics. In the calculations of the relationship
between two methods the experimental variance (de-
termined in day-to-day reproducibility tests) of both
methods was taken into account [4]. The SD of slope
and intercept were calculated with the simple formula
for linear regression. Significance was tested with Stu-
dent's t test.
Results
Table IV presents the day-to-day repro-
ducibility of the assays. At heparin levels in
the therapeutic range (300-800 U/l), the SD
is more or less proportional to the level
found. At lower heparin levels the SD seems
to be absolute, which tends to make esti-
mates of the heparin level below 100 U/l rel-
atively inaccurate. Those results were ob-
tained with the reference curves ranging from
0 to 800 U/1. The number oi days (n) listed
indicate the practical use ofthe assay. Origi-
nally, n was 24 for each assay. Reference
measurements, that would not allow a fair fit
of a curve through them, resulted in unsafe
data for clinicians. Such data were discarded
and the (n) in table IV was decreased by 1.
An example of a calculated reference
curve of the heparin assay based on thrombin
inactivation is the dashed line in ligure l.
This line was fitted through measurements
Plasma ATIII
pl pl
Hep Buffer I
200 pl
U/l,1tl
Using S-2222
Normal range
0 u/l
200 u/l
400 u/l
600 uil
800 u/l
Low range
0 u/l
50 uil
r00 u/l
r50 uil
200 u/l
100 100
100 100
100 100
100 100
100 100
100 100
100 100
100 100
100 100
100 r00
0 800
100 700
200 600
300 500
400 400
0 800
25 775
50 750
75 725
100 700
Using 5-2238 or Chromozym-Th
Normal range
0 u/l
200 u/l
400 u/l
600 u/l
800 u/l
Low range
0 u/l
50 uil
100 u/l
150 u/l
200 u/l
400 0
400 50
400 100
400 150
400 200
400 0 l
400 251
400 50r
400 751
400 l00r
50
50
50
50
s0
50
50
50
50
50
550
500
4s0
400
350
550
525
500
475
450
' Hep 100 U/1.
Table IIIb. Dilution procedure for reference sam-
ples of ATIII assays with 5-2238 or Chromozym-Th
o/o ATIII Plasma, pl Buffer II, pl
0
50
70
100
125
0
50
70
r00
100
r,000
950
930
900
700
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Table IV. Day-to-day reproducibility of the assays
CP
il
CP
I
Pool
3
PoolPool
I
Approximate heparin
concentration, U/l 75027080030050
Assay
Manual kits
Chrom Th, U/l
s-2222,U/l
57
t 8
(16)
628
t27(r2)
803
92
( l  5)
2t5
78
(18)
299
40
(22)
t,543
133
(13)
t,322
370
(4)
288
57
(17)
3 1 5
40
(22)
39
l9
(21)
Automated assays
Chrom Th, U/l
s-2238, U/l
s-2222,U/l
175
20
(23)
89
t 7
(22)
54
29
(24)
290
l 7
(23)
244
28
(23',)
206
56
(22\
765
53
(23\
758
55
(23)
1,390
238(r7)
1,353
J I J(r2)
1 ,377
219
(4)
-3
67
(23)
2 1 8
J J
(23)
105
57
(24)
796
86
(23)
For each assay the mean, the standard deviation and the number (in parentheses) of data points are given.
CP = Control plasma.
obtained at intervals of 200 U/l of heparin.
Extra measurements at 50-U/l intervals in
the low range (a) clearly show the dashed ref-
erence line not to be applicable there (0-200
U/l). It appeared that the extent of the deyia-
tions ofthe reference curves shown at the low
heparin concentrations was strongly depen-
dent upon the amount ofAtIII added, both in
the anti-Ila and in the anti-Xa test (results
not shown). This phenomenon can be
avoided by adding 100 pl of heparin
(2,500 U/l) to each vial of 10 ml ATIII solu-
tion (l U/ml), as is shown by the linear refer-
ence curve (o, solid line) in figure l. Identical
observations were made with factor Xa inac-
tivation (not shown).
Comparison of the assay that uses throm-
bin (with 5-2238) with the assay that employs
Xa (with 3-2222) were performed on deter-
minations in the range of 0-800 U/1. We
found an acceptable agreement between the
two methods (fre.2). The relationship Y (S-
2222) = a + b X (5-2238) showed an intercept
of 13 + l0u/l and a slope of 0.97 + 0.02.
Regression analysis was also done for sub-
populations selected by ATIII level (0-600/0,
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Table V. Relationship between anti-Xa and anti-
lla assays
Fig. l. Reference curves (200 U/l inter-
val measurements) of the heparin assay us-
ing 5-2238 (with thrombin) with (solid line)
and without (dashed line) heparin added to
the AIUI reagent. Connected by a dotted
line, intermediate measurements (50 U/l
intervals) in the low range axe depicted
(^).
Table VI. Comparison between Chromozym-Th
and 5-2238
ATIII a,U/l Sa, U/l b
level, o/o
Relationships between test results of heparin as-
says based on thrombin inactivation and measured
with s-2238 (x in the equation: y = a + b ' x) and based
on Xa inactivation (y), split up by level of AtUI. The
standard deviation ofintercepts (SJ as well as ofthe
slopes (Ss) are given. The results of both assays are
significantly not different (p > 0'01). The last column
shows the correlation coefficient (r).
Assay
Heparin
assay 14U/l 9 U/l 0.99 0.02 6't 0.97
AtUI
assay 1.00 0.05 7t  0 .87
Relationships (y = a + b' x) between results of
assays using 5-2238 (x) and results of assays using
Chromozym-Th (y). The standard deviations of inter-
cepts (SJ as well as ofthe slopes (56) are given. The
results ofboth assays are sigrrificantly (p > 0-01) not
different. The last column shows the correlation coef-
frcient (r).
For ATIII 100% is the activitv found in 1 ml of
pooled normal plasma and defined as I U.
SusuS5
4o/o3 %
0-60 20
60-80 0
80-120 31
0-200 13
0.92
1.00 0.02
0.93 0.05
0.97 0.02
2 1.00
4s 0.98
32 0.94
77 0.96
;
22
1 0
;  . : ' - ' . . : :  , - - ; ' ' - . . . . . J - , . . - ! - : . - . : r : . - - i , . : ' , . * .  - . .  : -  ; r ' - . r ' r l : : : : ; : i i * i < t t i ' ; i r . g + i ' . . . : r ' ;
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60-800/o and 80-1200/o AIIID. This did not
reyeal an influence of ATIII on this relation-
ship (table V). The results of both assays may
be considered similar because neither the
slope of the calculated relationship is signifi-
cantly different from 1.00 (p > 0.01) nor the
intercept is diflerent from 0 (p > 0.01).
We found a poor relationship between the
APTT and each of the chromogenic heparin
assays (fie. 3).
Assays using the substrates Chromozym-
Th and 5-2238 do not give significantly dif-
ferent results, either in the heparin or in the
ATIII determinations (table VI).
Discussion
An expected advantage of automated as-
says over manual assays is better reproduc-
ibility. For routine heparin determinations,
we consider assays acceptable only if the
standard deviation is less than 100/o of the
result in the therapeutic range (300-800 U/l).
The SD of the two automated heparin assays
based on thrombin inactivation (5-2238 or
Chrom-Th) were acceptable and evidently
lower than the SD ofthe assay based on fac-
tor Xa inactivation.
In routine practice we need for all tests
some control material in order to determine
the quality of the used reagents and instru-
ments. For quality control of the automated
as well as of the manual spectrophotometric
heparin assays the heparinised plasma pools
were as good as the tested control plasmas
Precichrom I and II, since the SD ofthe latter
two was as high as that of the pools. How-
ever, we prefer the heparinised plasma pools
because the value ofPrecichrom II was often
out ofrange, as can be deduced from the low
number of observations (n) in the last col-
umn in table IV. This can very well be due to
the fact that the commercially available con-
trol plasmas may contain other heparin prep-
arations than we used for the reference
curves.
Detailed reference measurements in the
low range (with 50 U/l plasma increments)
showed that the reference curves calculated
from measurements at high concentrations
do not apply here. We presume that this
deviation was caused by the neutralisation of
heparin (about 150 U/l plasma) by the AIUI
added.
We indeed found the neutralisation of
heparin in both assays to be related to the
concentration of the added ATIII reagent.
Table VII. Relationship between APTT and hepa-
nn assays
A I I I I a S " b S u n r
level, o/o
Assay using 5-2222
0-60 88 25
60-80 ro2 16
80-120 63 I I
0-200 83 I I
0.2'7 0.07
0.25 0.05
0.19 0.03
0.24 0.03
7
37
28
68
0.83
0.49
0.69
0.57
Assay using 5-2238
0-60 73
60-80 100
80-120 60
0-200 76
39 0.30 0.12 7 0.72
r7 0.24 0.05 40 0.53
12 0.22 0.03 29 0.71
11 0.27 0.03 7 l  0.60
Assay using Chromozym-Th
0-60 66 38 0.33 0.12 7 0.75
60-80 106 20 0.2r 0.06 38 0.47
80-120 62 t4 0.20 0.04 27 0.66
0-200 80 13 0.24 0.04 67 0.55
Relationships between APTT (x in the equation:
y = a + b . x) and results of heparin assays (y), split up
by level ofAtIII. The SD ofthe intercept (S") as well as
of the slope (Sr) are given. The last column shows
the correlation coeffrcient (r).
7
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Fig,2. Relationships between a heparin assay
based on thrombin inactivation with 5-2238 (x axis)
and the heparin assay based on factor Xa inactivation
wirh 5-2222 (y axis). See also table V.
Fig. 3. Relationships between spectrophotometric
determined heparin levels (x axis) and the APTT
(y axis); heparin assay with Chromozym-Th based on
thrombin inactivation. See also table VII.
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Since the ATIII concentration in the assay
based on thrombin inactivation is 4.5 times
the concentration in the assay based on factor
Xa inactivation, the error of the reference
curve is less apparent in the test based on fac-
tor Xa inactivation. This does not mean thal
this test is better but it does explain why
the assay based on thrombin inactivation
showed higher results for pool I and pool 2,
but lower results for pool 3 (table IV), than
the assay based on factor Xa inactivation.
To avoid this problem we added heparin
to the ATIII reagent to saturate the neutralis-
ing activity. Since the addition of heparin
influences the reference sample measure-
ments to the same extent as the patient
plasma measurements, this addition will not
change the standard deviation but only yield
a better fit ofthe reference curve through the
reference measurements at 0-200 U/1. Con-
sequently, the further assays were performed
with ATIII with heparin added (see'Materi-
als').
Yin et al. [5j showed that the heparin-
enhanced inactivation by ATIII of thrombin
is not the same as that of Xa. Several studies
have shown a diflerence in anti-Xa eflect and
anti-Ila effect between heparins of different
molecular weights and of different origins [6,
71. For the determination of plasma heparin
levels we may safely assume that the differ-
ence in behavior of heparin in the anti-Xa
assay as compared to the anti-Ila assay will
aflect the reference samples to the same ex-
tent as the individual patient plasmas. The
reference curve therefore holds for one type
of heparin only.
A similar test outcome for the anti-Xa as
for the anti-Ila assay was to be expected only
if the components of the heparin preparation
injected retained the same relative concentra-
tions in the patient plasma. The results
shown in figure 2 and table V make this plau-
sible. This study was performed with the
intravenous administration of heparin. Be-
cause subcutaneously injected heparin frac-
tions might not reach the intravascular com-
partment with similar kinetics, the current
study results may not simply be extrapolated
to this type of heparin administration.
Although it is sometimes suggested that
the interindividual variation of in APTT re-
sponse to heparin (partly) is due to variation
between individuals in concentration of clot-
ting factors or AIIII, there is no scientific or
clinical evidence for this claim.
The coe{Iicients of correlation between
the clotting assay and the spectrophotometric
assays are highly significant (p < 0.001, ta-
ble VII) and have been found before [8]. The
wide variation of intercepts and slopes of the
relationships between the spectrophotomet-
ric determinations and the clotting assay,
however, clearly demonstrate that the APTT
cannot be used to deduce a reliable estimate
of the heparin level. Selection of normal
ATIII levels yields the same conclusion (p >
0.05, results not shown).
As the results of the 3 automated spectro-
photometric heparin assays were not signifi-
cantly different, it is evident that the relation-
ships between APTT and each of the heparin
assays were the same. Which type of heparin
assay is to be used in the routine laboratory
for monitoring plasma heparin levels thus
has to be decided on the basis of the quality
of the spectrophotometric test and on practi-
cal considerations.
Although the diflerence in results is not
signihcant, the lower experimental error in
the assay based on thrombin inactivation
suggests a small advantage. Our preference
for this assay over the assay based on factor
Xa inactivation is also based on the fact that
: lc
.T
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the same reagents can be used for the heparin
determination as for the ATIII determination.
Moreover, in previous experiments we
showed that high heparin concentrations can
be measured with the anti-Ila method after
extreme dilution with buffer. No grounds
could be found to prefer either S-223g or
Chromozym-Th.
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